Hepion Pharmaceuticals Stock Today

HEPA Stock  USD 2.49  0.01  0.40%   

Performance

0 of 100

 
Low
 
High
Very Weak

Odds Of Distress

Less than 44

 
100  
 
Zero
Below Average
Hepion Pharmaceuticals is trading at 2.49 as of the 29th of March 2024, a -0.4 percent decrease since the beginning of the trading day. The stock's open price was 2.5. Hepion Pharmaceuticals has about a 44 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Hepion Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of April 2022 and ending today, the 29th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
11th of February 2014
Category
Healthcare
Classification
Health Care
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey. The company has 4.34 M outstanding shares of which 56.6 K shares are currently shorted by private and institutional investors with about 0.53 trading days to cover. More on Hepion Pharmaceuticals

Moving together with Hepion Stock

  0.62MBRX Moleculin Biotech Financial Report 9th of May 2024 PairCorr

Moving against Hepion Stock

  0.64CLVRW Clever Leaves HoldingsPairCorr
  0.45MGNX MacroGenics Financial Report 14th of May 2024 PairCorr

Hepion Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Hepion Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Hepion Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO, DirectorRobert Foster
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Hepion Pharmaceuticals report their recommendations after researching Hepion Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Hepion Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Hepion Pharmaceuticals. The Hepion consensus assessment is calculated by taking the average forecast from all of the analysts covering Hepion Pharmaceuticals.
Financial Strength
Based on the key indicators related to Hepion Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Hepion Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April. Financial strength of Hepion Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities9.5 M9.1 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total3.8 M2.9 M
Significantly Up
Slightly volatile
Total Assets72.7 M69.3 M
Sufficiently Up
Slightly volatile
Total Current Assets68.2 M65 M
Sufficiently Up
Slightly volatile
Hepion Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Hepion Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Hepion Pharmaceuticals' financial leverage. It provides some insight into what part of Hepion Pharmaceuticals' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Hepion Pharmaceuticals' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Hepion Pharmaceuticals deploys its capital and how much of that capital is borrowed.
Liquidity
Hepion Pharmaceuticals cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 53.61 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Hepion Pharmaceuticals has a current ratio of 8.59, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Hepion Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Hepion Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hepion Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hepion to invest in growth at high rates of return. When we think about Hepion Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Change In Cash

(37.87 Million)
Hepion Pharmaceuticals (HEPA) is traded on NASDAQ Exchange in USA. It is located in 399 Thornall Street, Edison, NJ, United States, 08837 and employs 25 people. Hepion Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.84 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Hepion Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Hepion Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Hepion Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 4.34 M outstanding shares of which 56.6 K shares are currently shorted by private and institutional investors with about 0.53 trading days to cover. Hepion Pharmaceuticals currently holds about 59.15 M in cash with (36.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.78.
Check Hepion Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
The market capitalization of Hepion Pharmaceuticals is currently $10.84 Million. Roughly 82.0 (percent) of Hepion Pharmaceuticals outstanding shares are held by general public with 0.38 % owned by insiders and only 17.3 pct. by outside corporations. Be advised that no matter how volatile the entity is, if the real value of the firm is more than the value suggested by the market, you should consider buying it.
Check Hepion Ownership Details

Hepion Stock Price Odds Analysis

What are Hepion Pharmaceuticals' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Hepion Pharmaceuticals jumping above the current price in 90 days from now is about 41.62%. The Hepion Pharmaceuticals probability density function shows the probability of Hepion Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.761. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Hepion Pharmaceuticals will likely underperform. Additionally, hepion Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming NYSE Composite.
  Odds Below 2.49HorizonTargetOdds Above 2.49
58.28%90 days
 2.49 
41.62%
Based on a normal probability distribution, the odds of Hepion Pharmaceuticals to move above the current price in 90 days from now is about 41.62 (This Hepion Pharmaceuticals probability density function shows the probability of Hepion Stock to fall within a particular range of prices over 90 days) .

Hepion Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Hepion Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Hepion Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Hepion Pharmaceuticals' value.
InstituionRecorded OnShares
Group One Trading, Lp2023-09-30
339
Wells Fargo & Co2023-09-30
28.0
Barclays Plc2023-09-30
16.0
Jpmorgan Chase & Co2023-09-30
5.0
Ubs Group Ag2023-09-30
2.0
Signaturefd, Llc2023-09-30
1.0
Hanson Mcclain Inc2023-09-30
1.0
Harbor Investment Advisory, Llc2023-09-30
1.0
Global Retirement Partners, Llc.2023-09-30
1.0
Armistice Capital, Llc2023-09-30
397.6 K
Vanguard Group Inc2023-09-30
165.5 K
View Hepion Pharmaceuticals Diagnostics

Hepion Pharmaceuticals Historical Income Statement

Hepion Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Hepion's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Hepion Pharmaceuticals revenue and expense. Hepion Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Hepion Pharmaceuticals' Depreciation And Amortization is projected to decrease significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 52.7 M, whereas Selling General Administrative is forecasted to decline to about 6.6 M. View More Fundamentals

Hepion Stock Against Markets

Picking the right benchmark for Hepion Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Hepion Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Hepion Pharmaceuticals is critical whether you are bullish or bearish towards Hepion Pharmaceuticals at a given time. Please also check how Hepion Pharmaceuticals' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Hepion Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Performance Analysis Now

   

Performance Analysis

Check effects of mean-variance optimization against your current asset allocation
All  Next Launch Module

Hepion Pharmaceuticals Corporate Directors

Hepion Pharmaceuticals corporate directors refer to members of a Hepion Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Hepion Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Hepion Pharmaceuticals' board members must vote for the resolution. The Hepion Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Thomas AdamsIndependent DirectorProfile
Timothy BlockIndependent DirectorProfile
John BrancaccioIndependent DirectorProfile
Arnold LippaIndependent DirectorProfile

How to buy Hepion Stock?

Before investing in Hepion Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Hepion Pharmaceuticals. To buy Hepion Pharmaceuticals stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Hepion Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Hepion Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Hepion Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Hepion Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Hepion Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Hepion Stock please use our How to Invest in Hepion Pharmaceuticals guide.

Already Invested in Hepion Pharmaceuticals?

The danger of trading Hepion Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Hepion Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Hepion Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Hepion Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Hepion Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hepion Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hepion Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hepion Pharmaceuticals Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Hepion Stock analysis

When running Hepion Pharmaceuticals' price analysis, check to measure Hepion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hepion Pharmaceuticals is operating at the current time. Most of Hepion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hepion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hepion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hepion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Commodity Directory
Find actively traded commodities issued by global exchanges
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Is Hepion Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hepion Pharmaceuticals. If investors know Hepion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hepion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(12.42)
Return On Assets
(0.63)
Return On Equity
(1.18)
The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hepion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hepion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.